medigraphic.com
ISSN 1684-1824 (Electronic)

2021, Number 5

<< Back Next >>

Rev Méd Electrón 2021; 43 (5)

Clinical characteristics and evolution of symptoms in patients with COVID-19

Acosta-González FA, González-Tabares R, Oliva-Villa E, Rodríguez-Reyes SF, Cabeza-Echevarría I, astelnau-Sánchez, AR

Language: Spanish
References: 20
Page: 1310-1327
PDF size: 1147.76 Kb.


ABSTRACT

Introduction: many cases of covid-19 are asymptomatic when admitted to the hospital. The development of symptoms may be related to the therapies used.
Objective: to characterize clinically the patients infected with SARS-CoV-2 and the evolution of symptoms in relation to admission, in the Military Hospital Dr. Mario Muñoz Monroy, of Matanzas.
Materials and methods: retrospective study of clinical records of SARS-CoV-2-confirmed patients admitted up to June 26, 2020. 145 patients were studied, divided into two groups: symptomatic and asymptomatic ones at admission. Demographic data, personal pathological history, symptoms and evolution, humoral parameters, treatment, hospital stay and complications were collected. The Chi square and Mann-Whire U tests were used, depending on the type of variable.
Results: most patients were symptomatic at admission. Asymptomatic ones predominated only up to 19 years. Hypertensive, diabetic and renal impaired patients had a higher proportion of symptoms at admission. A small group (n = 38) never developed symptoms. Cough, general discomfort, fever, pharyngeal pain, nasal congestion, anosmia and shortness of breath were the predominated symptoms. Diarrhea, dyspepsia and vomiting prevailed after admission. The symptomatic patients showed higher liver enzyme values, more low respiratory infection and respiratory distress, and also had more extended hospital stay, admission to intensive care and deceases.
Conclusions: more than half of the patients were admitted with predominance of general and respiratory symptoms. After admission, digestive symptoms predominated, possibly related to the therapies used. Symptomatic patients on admission had worse humoral parameters, more complications and longer hospital stay.


REFERENCES

  1. Organización Mundial de la Salud. Neumonía de causa desconocida - China 2020. Brotes epidémicos [Internet].Suiza: OMS; 5 de enero de 2020[citado 15/02/2021]. Disponible en: Disponible en: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/es/

  2. ChenJ, QiT, LiuL, et al. Clinical progression of patients with COVID-19 in Shanghai, China. Journal of infection. 2020;80(5):e1-e6. Citado en PubMed; PMID: 32171869.

  3. PanL, MuM, YangP, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020;115(5):766-73. Citado en PubMed; PMID: 32287140.

  4. KampsBS, HoffmannC. COVID reference [Internet]. Germany: Steinhäuser Verlag; 2020 [citado 15/02/2021]. Disponible en: Disponible en: https://www.agoaragon.com/wp-content/uploads/2020/04/CovidReference01_es.pdf.pdf

  5. LiX, XuS, YuM, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-8. Citado en PubMed; PMID: 32294485.

  6. González TabaresR, Acosta GonzálezFA, Oliva VillaE, et al. Predictores de mal pronóstico en pacientes con la COVID-19. Rev Cubana Med Mil[Internet]. 2020[citado 15/02/2021];49(4):e0200918. Disponible en: Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/918

  7. Almeida CruzY, Reyes CarmonaS, Guerra ValdésEA, et al. Covid19CubaData[Internet]. La Habana: Covid19CubaData; 2020 [citado 01/09/2020]. Disponible en: https://covid19cubadata.github.io/#cuba

  8. YangY, XiaoZ, YeK, et al. SARS-CoV-2: characteristics and current advances in research. Virol J. 2020;17(1):117. Citado en PubMed; PMID: 32727485.

  9. DongY, MoX, HuY, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics [Internet]. 2020 [citado 15/02/2021];145(6):e20200702. Disponible en: Disponible en: https://pediatrics.aappublications.org/content/pediatrics/145/6/e20200702.full.pdf

  10. GarazzinoS, MontagnaniC, DonàD, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Eurosurveillance [Internet]. 2020[citado 15/02/2021];25(18):1-4. Disponible en: Disponible en: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.18.2000600?crawler=true

  11. Serra ValdésMA. COVID-19. De la patogenia a la elevada mortalidad en el adulto mayor y con comorbilidades. Rev habanera cienc méd[Internet]. 2020 [citado 15/02/2021];19(3):e3379. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2020000300004&nrm=iso

  12. AlbitarO, BallouzeR, OoiJP, et al. Risk factors for mortality among COVID-19 patients. Diabetes Research and Clinical Practice[Internet]. 2020 [citado 15/02/2021]; 166:108293. Disponible en: Disponible en: https://www.diabetesresearchclinicalpractice.com/action/showPdf?pii=S0168-8227%2820%2930545-3

  13. HenryBM, LippiG. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020;52(6):1193-4. Citado en PubMed; PMID: 32222883.

  14. HuangS, WangJ, LiuF, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertension Research[Internet]. 2020[citado 15/02/2021];43(8):824-31. Disponible en: Disponible en: https://www.nature.com/articles/s41440-020-0485-2.pdf

  15. YaoTT, QianJD, ZhuWY, et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus - A possible reference for coronavirus disease‐19 treatment option. J Med Virol. 2020;92(6):556-63. Citado en PubMed; PMID: 32104907.

  16. FelsensteinS, HerbertJA, McNamaraPS, et al. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215:108448. Citado en PubMed; PMID: 32353634.

  17. CaoZ, LiT, LiangL, et al. Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. PLoS ONE. 2020;15(6):e0234764. Citado en PubMed; PMID: 32555674.

  18. CummingsMJ, BaldwinMR, AbramsD, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet. 2020;395(10239):1763-70. Citado en PubMed; PMID: 32442528.

  19. Herrera-Lasso RegásV, Dordal CullaMT, Lleonart-BellfillR. Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2. Med Clin (Barc). 2020;155(10):448-53. Citado en PubMed; PMID: 32718715.

  20. BerenguerJ, RyanP, Rodríguez BañoJ, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;26(11):1525-36. Citado en PubMed; PMID: 32758659.




2020     |     www.medigraphic.com